<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489267</url>
  </required_header>
  <id_info>
    <org_study_id>20111031SCA</org_study_id>
    <secondary_id>20111031limin</secondary_id>
    <nct_id>NCT01489267</nct_id>
  </id_info>
  <brief_title>A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation</brief_title>
  <acronym>SCA</acronym>
  <official_title>The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Chinese Armed Police Forces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary cerebellar ataxia is a type of autosomal dominant genetic disease, lesions mainly
      involving the cerebellum, but the spinal cord and cranial nerves may also be some
      involvement. A total of 20 molecularly diagnosed SCA1 patients divided in two groups. One
      group accepted for the treatment of stem cell transplantation,the other group will be the
      control. Purpose of this project to prove that allogeneic umbilical cord mesenchymal stem
      cells are applied to clinical safely, and in the treatment of hereditary cerebellar ataxia is
      valid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After admission the patients accepted transplantation would receive physical examination,
      blood and urine tests, electrocardiogram, electrophysiologic study;evaluation of SCA1
      symptoms (balance, walking, dexterity, tremor, memory, mood and concentration),then stem cell
      therapy：after stem cell prepared, the patients accepted 4 times stem cell transplantations
      through lumbar puncture, the time is 3-5days between two treatments. The control only receive
      evaluation of SCA1 symptoms .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood test</measure>
    <time_frame>within one week before transplantation</time_frame>
    <description>white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve functional evaluation</measure>
    <time_frame>within one week before transplantation</time_frame>
    <description>Timed-up-and-go test ,5 minutes down-and-up test
ICARS score
Modified Falls Efficacy Scale
Berg balance assessment
Tremor Rating Scale:
Part A - Tremor location/severity rating
Part B -Handwriting and drawings
Part C - Functional disabilities resulting from tremor
Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood test</measure>
    <time_frame>1 month after transplantation</time_frame>
    <description>white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood test</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood test</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood test</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve functional evaluation</measure>
    <time_frame>1 month after transplantation</time_frame>
    <description>Timed-up-and-go test ,5 minutes down-and-up test
ICARS score
Modified Falls Efficacy Scale
Berg balance assessment
Tremor Rating Scale:
Part A - Tremor location/severity rating
Part B -Handwriting and drawings
Part C - Functional disabilities resulting from tremor
Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve functional evaluation</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>Timed-up-and-go test ,5 minutes down-and-up test
ICARS score
Modified Falls Efficacy Scale
Berg balance assessment
Tremor Rating Scale:
Part A - Tremor location/severity rating
Part B -Handwriting and drawings
Part C - Functional disabilities resulting from tremor
Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve functional evaluation</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>Timed-up-and-go test ,5 minutes down-and-up test
ICARS score
Modified Falls Efficacy Scale
Berg balance assessment
Tremor Rating Scale:
Part A - Tremor location/severity rating
Part B -Handwriting and drawings
Part C - Functional disabilities resulting from tremor
Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve functional evaluation</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Timed-up-and-go test ,5 minutes down-and-up test
ICARS score
Modified Falls Efficacy Scale
Berg balance assessment
Tremor Rating Scale:
Part A - Tremor location/severity rating
Part B -Handwriting and drawings
Part C - Functional disabilities resulting from tremor
Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinal test</measure>
    <time_frame>within one week before transplantation</time_frame>
    <description>proteinum、akaryocyte、α1- microglobulin、β2- microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology examination</measure>
    <time_frame>within one week before transplantation</time_frame>
    <description>somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinal test</measure>
    <time_frame>1 month after transplantation</time_frame>
    <description>proteinum、akaryocyte、α1- microglobulin、β2- microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinal test</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>proteinum、akaryocyte、α1- microglobulin、β2- microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinal test</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>proteinum、akaryocyte、α1- microglobulin、β2- microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinal test</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>proteinum、akaryocyte、α1- microglobulin、β2- microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology examination</measure>
    <time_frame>1 month after transplantation</time_frame>
    <description>somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology examination</measure>
    <time_frame>3 months after transplantation</time_frame>
    <description>somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology examination</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology examination</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hereditary Cerebellar Ataxia.</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients in the group accept stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10`7 cells).</description>
    <arm_group_label>Stem cell transplantation</arm_group_label>
    <other_name>Cell therapy.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-65 years of age

          2. Molecularly diagnosed SCA1

        Exclusion Criteria:

          1. Cognitively impaired individuals

          2. Schizophrenics

          3. Patients with severe kidney and liver disease, epilepsy, heart disease, pulmonary
             disease, cardiac arrhythmia, diabetes insipidus, leukemia and some other central
             neural disease (such as Parkinson disease, accidence of brain vascular et al)

          4. Age less than 18 years, age greater than 65 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihua An, doctor</last_name>
    <role>Study Director</role>
    <affiliation>director of neural stem cell transplantation department in general hospital of chinese armed police forces</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yihua An</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>June 18, 2012</last_update_submitted>
  <last_update_submitted_qc>June 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebellar ataxia</keyword>
  <keyword>hereditary disease</keyword>
  <keyword>stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

